NDA of BCMA CAR T Zevor-cel (CT053) accepted by China NMPA
Prof. Wenming Chen, the principal investigator of the CT053-MM-01 study, Director of Hematology Department, Beijing Chao-Yang Hospital, Capital Medical University, said: “Results from the LUMMICAR-1 study show that the fully human autologous BCMA CAR T-cell product, zevor-cel, demonstrated strong and durable efficacy in patients with relapsed/refractory multiple myeloma, and was generally well tolerated. We are delighted to see that the NDA of this CAR T-cell product with independent intellectual property rights has been officially accepted by the NMPA, and we are looking forward to its early launch and bringing clinical benefits to Chinese patients with relapsed/refractory multiple myeloma.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.